Abstract: A cooling system having a cooling chamber including a surface defining one or more openings. A surface is configured to hold at least one container. An access door provides access to the cooling chamber. A refrigeration system is configured to cool the cooling chamber by forcing cool airflow through the one or more openings in the surface. The airflow through each of the one or more openings may be similar.

Abstract: The present invention provides an ophthalmic formulation consisting essentially of one or more pharmaceutically acceptable excipients; a pharmaceutically active compound that is capable of reducing the amount of inflammatory neutrophil product on the ocular surface; and optionally a second pharmaceutically active compound selected from the group consisting of a steroid, an anti-inflammatory agent, a mucolytic agent and a combination thereof. In particular, the present invention provides an ophthalmic formulation where the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory and immunological ocular surface disease that can cause symptoms of ocular discomfort, mucocellular aggregates/debris in tear film, symblepheron formation, fornix foreshortening, eyelid margin/conjunctival keratinization, corneal neovascularization/pannus, subconjunctival fibrosis, and herpetic eye disease.

Abstract: Systems and method for idle loop detection and control are disclosed. A processor operates in operating modes including an active mode and a disabled mode, and an interconnect bus is coupled between the processor and one or more additional electronic circuits. Logic within the processor is coupled to snoop the interconnect bus, and the logic is programmed to detect a new idle loop based upon repeated instructions on the interconnect bus and to place the processor in the disabled mode based upon execution of the new idle loop, which represents a previously unknown idle loop for the processor. Further, the logic can be programmed to store state data for the processor when the new idle loop is detected, and the logic can also be programmed to place the processor in the active mode based upon detection of a wakeup event for the new idle loop on the interconnect bus.

Abstract: A process for the recovery of polymer-grade (meth)acrylic acid, in the absence of organic solvent, from a gaseous reaction mixture comprising (meth)acrylic acid obtained by gas-phase oxidation of a precursor of the (meth)acrylic acid, the process carried out in a plant comprising at least one dehydration column and one finishing column, being characterized by the presence of at least one chemical treatment agent targeted at reducing the content of residual aldehydes. (Meth)acrylic acid obtained according to the invention meets criteria of high quality allowing it to be used in the manufacture of acrylic polymers, in particular for superabsorbents. This grade is also known as glacial acrylic acid GAA.

Abstract: A semiconductor device including scan configuration circuitry that reconfigures latches of the device into a scan chain in response to assertion of a scan enable control signal, and scan control circuitry including delay circuitry, scan enable circuitry, evaluation circuitry, and scan reset circuitry. The scan reset circuitry keeps each of the secure latches in a predetermined reset state until assertion of both an evaluation signal and a scan mode signal. The delay circuitry includes N series-coupled flip-flops selected from different cell libraries detecting assertion of the scan mode signal and asserting a delay output signal only after N transitions of a test clock. The scan enable circuitry asserts the scan enable control signal when a scan enable command signal and the delay output signal are both asserted. The evaluation circuitry asserts the evaluation signal only when a collective state of the delay circuitry has achieved a predetermined state.

Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Abstract: Systems and methods include, responsive to a Wi-Fi client device providing a password for a zone of a Wi-Fi network, determining a status of the Wi-Fi client device; when the status is unknown, placing the client device in a holding area associated with the zone, wherein the client device is connected to the Wi-Fi network while in the holding area and has restricted access that is less than full access to the zone in an allowed zone; responsive to placing the client device in the holding area, causing a notification to an administrator that the client device is in the holding area; and with the client device in the holding area, one of moving the Wi-Fi client device to the allowed area, moving the client device to a rejected area for the zone, and leaving the client device in the holding zone, based on any input or lack thereof.

Abstract: The present invention concerns a method of decarbonating a gas stream containing from 15% to 60% carbon dioxide, by passage of the said gas stream over a zeolitic agglomerate comprising at least one binder and at at least one zeolite, and having a mesoporous volume of between 0.02 cm3·g?1 and 0.15 cm3·g?1 and a mesoporous volume fraction of between 0.1 and 0.5, preferably between 0.15 and 0.45.

Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Abstract: The present invention relates to an improved process for the preparation of Valacyclovir or pharmaceutically acceptable salts thereof, which comprises reaction of amine-protected Valacyclovir or its salt with deprotecting agent in a continuous flow reactor.

Abstract: The present invention provides a preservative free ophthalmic formulation. In particular, the ophthalmic formulations of the invention are aqueous formulations comprising nanoemulsion of oil. The present invention also provides a method for treating an eye disorder. In one particular embodiment, the invention provides methods for treating dry eye syndrome using an preservative free formulation comprising a nanoemulsion of oil and alpha 2 adrenergic agonist, pharmaceutically acceptable salt thereof or a mixture thereof. In particular, the alpha 2 adrenergic agonist of the invention has a higher alpha 2A agonist activity compared to alpha 2B agonist activity. This invention also provides a preservative free ophthalmic composition comprising a nanoemulsion of oil, a therapeutically effective amount of an alpha 2 adrenergic agonist, a pharmaceutically acceptable salt thereof or a combination thereof as an active ingredient for treating a dry eye syndrome.

Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

Abstract: A device is disclosed. The device includes a read-only memory (ROM), a random key generator, a lifecycle controller, an access port and a processor. The processor is configured, based on a lifecycle status, to cause the random key generator to generate a secret key and store the secret key in the ROM. The lifecycle controller is configured to disable an external access via the access port until the secret key is stored in the ROM.

Abstract: A system for securing a secret word during a read of the secret word from a read-only memory (ROM) is disclosed. The system includes a memory controller coupled to the ROM and a random number generator coupled to the memory controller. The random number generator is configured to generate a random number. The system further includes a number shuffler coupled to the random number generator and the memory controller. The number shuffler is configured to generate a bit read order based on the random number and the memory controller is configured to read bits of the secret word from the ROM according to the bit read order.

Abstract: Coolers for dispensing products, such as beverages, having multiple doors for accessing a single product compartment. A cooler may include a housing defining a product compartment; a top door coupled to a top surface of the housing at a hinge, the top door comprising a curved transparent panel; a vertical door coupled to a vertical front surface of the housing; a collapsible shelf disposed in the product compartment that is configured to move between an extended position and a retracted position; and a lower shelf disposed below the collapsible shelf in the product compartment. A product disposed on the collapsible shelf may be accessible through the top door when the collapsible shelf is in the extended position and a product disposed on the lower shelf may be accessible through the top door when the collapsible shelf is in the retracted position.

Abstract: The present invention provides a composition comprising two or more of the following pharmaceutically active compounds: (i) an alpha 2 adrenergic agonist; (ii) a corticosteroid; (iii) a lymphocyte function-associated antigen antagonist; (iv) a non-steroidal anti-inflammatory drug (NSAID); (v) a sodium channel blocker; and (vi) an antibiotic, provided at least one of the pharmaceutically active compound is selected from the group consisting of (i) alpha 2 adrenergic agonist and (ii) corticosteroid.

Abstract: In accordance with an embodiment, described herein is a system and method for optimizing cloud infrastructure through client request classification in a cloud computing environment. The cloud infrastructure can include one or more high-compute infrastructure instances, and one or more standard-compute infrastructure instances. Each request received at a load balancer can be checked against a request classification cache, to determine whether the request has been classified, and if it has been classified, whether the request can be routed to a high-compute infrastructure instance or a standard-compute infrastructure instance based on a classification of the request. An unclassified request can be classified based on a plurality of request parameters, and threshold values derived from the cloud infrastructure; and can be stored in the request classification cache. Classified requests in the classification cache can be provided to a cloud vendor for use in optimizing the cloud infrastructure.

Abstract: A system and method for analyzing risk factors to enhance the quality of program code have been disclosed. The risks are identified and evaluated, post which test cases are defined for each of the identified risk factors. Further, the defect density, code complexity and change rate corresponding to each of the test cases is determined. Risk profiles are created for each of the test cases. The risk profiles are categorized based on defect density, complexity of the code and change rate. The test cases are evaluated depending upon the risk posed by new scripts added to the program code. The scripts need to be executed for satisfying a necessary and sufficient condition are decided based on the correlation between program code files, activities on those files, defects corresponding to those files and test cases used to test those defects.